Daily Newsletter

14 August 2023

Daily Newsletter

14 August 2023

HebeCell and Logomix partner to develop PSC-NK cells

The off-the-shelf ProtoNK cell products treat cancer, viral infections and autoimmune conditions.

Vishnu Priyan August 14 2023

Biotechnology company HebeCell has entered a strategic collaboration with synthetic biology company Logomix to research and develop gene-edited natural killer (NK) cells.

The companies will also work on discovering genetic alterations that could produce next-generation designer NK cells.

Logomix will offer its genome editing expertise to HebeCell to develop next-generation designer protoNK cells. 

By merging a pluripotent stem cell (PSC)-based platform with genome-editing expertise, the companies will expand and expedite new development to check for de novo genetic alterations that improve the protoNK cells’ persistence and efficacy against cancers.

HebeCell CEO John Lu stated: “We know our protoNK cells are strong cytotoxic cells. Our goal is to make PSC-derived protoNK more efficacious in vivo.

“This collaboration expands our efforts to develop unique NK cell therapies, and has the potential to create something new and never seen before in the NK therapeutic field.”

Established in 2016, HebeCell focuses on the development of NK cell therapeutics, leveraging its 3D PSC platform.

The off-the-shelf ProtoNK cell products treat cancer, viral infections and autoimmune conditions. 

Logomix CEO Taiki Ishikura stated: “Logomix’s proprietary technology, Geno-Writing, is a genome-writing platform that grants cell therapy developers unprecedented freedom to screen, design and write in large-scale genomic alterations in human cells. 

“Because our technology allows Mb-scale and scarless modifications, [when] applied to any sequences at either or both alleles it is an ideal tool to create a source of allogeneic cell therapy with desired gene edits.”

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close